Status:
COMPLETED
Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Bronchiolitis
Apnea
Eligibility:
All Genders
1-4 years
Phase:
NA
Brief Summary
Viral bronchiolitis is the most common lower respiratory tract infection of infancy. Apnea is a complication of bronchiolitis, reported in 16 - 21% of cases. Caffeine, a trimethylxanthine, acts as an ...
Detailed Description
Study area/setting: Pediatric emergency center Al-Sadd, (PEC) is the main pediatric emergency centre in the state of Qatar with approximately 200,000 visits annually. It has a capacity of 42 observat...
Eligibility Criteria
Inclusion
- Infants ≤4 months of age, presenting to pediatric emergency center Al-Sadd, from September 2011 to May 2014, with a diagnosis of viral bronchiolitis associated with apnea.
Exclusion
- Hypersensitivity to caffeine.
- Patients on caffeine treatment.
- Cardiovascular congenital abnormalities.
- Infants with a previous diagnosis of gastroesophageal reflux disease.
- Hypoglycemia and/or electrolytes disorders.
- Suspected sepsis.
- Seizure disorders.
- Inborn errors of metabolism.
- Renal and/or hepatic impairment.
- Major congenital anomalies of the upper and lower respiratory tract (severe tracheomalacia, trachea-esophageal fistula, diaphragmatic hernia, congenital lobar emphysema, congenital cystic adenomatoid malformation).
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01435486
Start Date
November 1 2011
End Date
November 1 2014
Last Update
April 1 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric emergency center, Hamad Medical Corporation
Doha, Baladīyat ad Dawḩah, Qatar, 3050